Literature DB >> 92362

Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses.

E De Clercq.   

Abstract

Suramin--a well-known antitrypanosomal agent--was found to exert a strong inhibitory effect on the RNA-directed DNA polymerase (reverse transcriptase) activity of several oncornaviruses such as Moloney murine leukemia virus, murine Rauscher leukemia viruses, Moloney murine sarcoma virus and avian myeloblastosis virus. Inhibition of enzyme activity was obtained with both endogenous viral RNA and (A)n . oligo(dT) as the template-primer. Suramin effected a 50% inhibition of the reverse transcriptase activity of oncornaviruses at a concentration range of 0.1--1 microgram/ml. In this aspect it compared favorably to ethidium bromide, another trypanocide drug which is considered as one of the most powerful inhibitors of oncornaviral DNA polymerases. The inhibition of reverse transcriptase activity by suramin was competitive with the template-primer, (A)n . oligo(dT), suggesting that the drug may interact with the template-primer binding site of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92362     DOI: 10.1016/0304-3835(79)90017-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  55 in total

1.  [Effect of suramin on proliferation and migration of lens epithelial cells in vitro].

Authors:  P W Rieck; J Kriegsch; C Jaeckel; C Hartmann
Journal:  Ophthalmologe       Date:  2004-01       Impact factor: 1.059

2.  Identification of Rift Valley fever virus nucleocapsid protein-RNA binding inhibitors using a high-throughput screening assay.

Authors:  Mary Ellenbecker; Jean-Marc Lanchy; J Stephen Lodmell
Journal:  J Biomol Screen       Date:  2012-05-29

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

Authors:  Danny Chen; Sae Heum Song; M Guillaume Wientjes; Teng Kuang Yeh; Liang Zhao; Miguel Villalona-Calero; Gregory A Otterson; Rhonda Jensen; Michael Grever; Anthony J Murgo; Jessie L-S Au
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 5.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

6.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

7.  The effect of suramin on healing adult rodent dermal wounds.

Authors:  J Chamberlain; M Shah; M W Ferguson
Journal:  J Anat       Date:  1995-02       Impact factor: 2.610

8.  Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.

Authors:  C Schiller; A Spittler; M Willheim; Z Szépfalusi; H Agis; M Köller; M Peterlik; G Boltz-Nitulescu
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

9.  Mass spectrometric molecular-weight determination of highly acidic compounds of biological significance via their complexes with basic polypeptides.

Authors:  P Juhasz; K Biemann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

Authors:  E Matthes; P Langen; M von Janta-Lipinski; H Will; H C Schröder; H Merz; B E Weiler; W E Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.